Table 2.

Ratios of significant changes of specific metabolites by stage of CKD (P≤0.05), mean values, and P values

Fold of ChangeMean ± SDP Value
Stages 3/2Stages 4/2Stages 4/3CKD Stage 2CKD Stage 3CKD Stage 4Stages 3/2Stages 4/2Stages 4/3
Altered arginine metabolism
 Dimethylarginine (SDMA + ADMA)8.14.80.497±0.1334.01±2.272.40±1.777.9E-050.010.17
 Citrulline1.61.3a0.825±0.1941.30±0.5861.08±0.3620.030.08
 Ornithine0.280.164.33±1.391.19±1.320.683±0.3342.0E-41.4E-06
 Arginine1.5a1.5a0.675±0.2381.02±0.4801.03±0.5590.060.10
Elevated coagulation/inflammation
 Fibrinopeptide A6898270.002±0.0011.03±0.7651.24±0.7953.0E-41.1E-14
 Phosphorylated fibrinopeptide A18452.50.045±0.0170.818±0.6832.06±2.620.0024.4E-080.04
 Proline-hydroxyproline2.54.50.466±0.2511.16±1.262.08±1.680.038.3E-05
Impaired carboxylate anion transport
 γ-Glutamylleucine1.30.821±0.2831.07±0.1610.03
 γ-Glutamylisoleucine1.61.70.670±0.1961.12±0.4401.18±0.5100.010.01
 γ-Glutamylglutamine3.84.80.275±0.1661.05±0.4171.31±0.3495.5E-058.9E-06
 γ-Glutamylphenylalanine1.51.30.903±0.2401.31±0.4801.17±0.1810.030.01
 CMPF18.3a23.60.307±0.2795.61±11.97.23±7.200.065.0E-4
Decreased adrenal steroid hormone production
 Dehydroisoandrosterone sulfate0.551.48±0.8780.819±0.6850.04
 4-androsten-3-β,17-β-diol disulfate0.263.91±3.761.02±0.9580.01
  • ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine; CMPF, 3-Carboxy-4-methyl-5-propyl-2- furanpropanoate.

  • a 0.1>P>0.05.